October 1, 2007


Lyme Disease: When Symptoms Don’t Improve


Risks Associated with Long-term Antibiotic Therapy

Long-term antibiotic therapy for patients with purported chronic Lyme disease or post-Lyme disease symptoms can cause considerable harm for patients and public health, such as:

  • adverse reactions following ceftriaxone administration, including life-threatening anaphylaxis and biliary complications requiring cholecystectomy
  • infection of the intravenous catheter, including Candidemia, which can result in death
  • fostering the development of other drug-resistant infections

 

The vast majority of patients with Lyme disease can be treated with a short course of antibiotic therapy and will recover fully. But for the small percentage of patients whose symptoms don’t improve (roughly 5 percent by some estimates), what is an ID clinician to do?

Noted experts Allen C. Steere, MD, FIDSA, of Harvard Medical School and Gary P. Wormser, MD, FIDSA, of New York Medical College offered their advice during a Meet–the-Professor session on Lyme disease. Both speakers were authors of IDSA’s 2006 practice guidelines on Lyme disease as well as a recent review article in the New England Journal of Medicine on “A Critical Appraisal of ‘Chronic Lyme Disease.’” (N Engl J Med 2007;357:50-58)

Different terms have been used to describe patients who continue to experience symptoms (see sidebar). According to Drs. Steere and Wormser, the term “chronic Lyme disease,” which implies chronic infection with Borrelia burgdorferi, is a misnomer, and the use of prolonged antibiotic treatments is unwarranted and can cause patients significant harm. Nevertheless, physicians and laypeople who believe in the existence of chronic Lyme disease have been vocal in championing their cause.

In patients with newly diagnosed Lyme disease, Dr. Wormser noted that it’s important to provide anticipatory counseling, so that patients understand that it may take several weeks to months for symptoms to resolve. Patients should be told that the internet contains many sources of misinformation. Many patients with post-Lyme disease symptoms fear that their symptoms indicate that they have a chronic infection that could cause neurologic damage, he said. It’s important to address those concerns.

The speakers offered the following advice to clinicians who are referred a patient who is purported to have chronic Lyme disease:

  • Review the symptoms, tick exposure, and lab data.
  • Emphasize the non-specific nature of symptoms.
  • Discuss the risks of unnecessary antibiotic treatment (see sidebar).
  • Thoroughly evaluate the patient for other medical conditions that could explain the symptoms.
  • If there is no specific treatment indicated, provide emotional support and symptomatic management
  • Explain in clear and empathetic language that there is no medication such as an antibiotic to cure the condition.

Caring for a patient who has no objective manifestations of an infection can be frustrating for an ID clinician. Still, Dr. Wormser urged his audience, “Don’t abandon these patients.” Doing so leaves them vulnerable to misinformation and a treatment plan that is expensive, unnecessary, and potentially dangerous.


Post-Lyme or Chronic Lyme?

post-Lyme disease symptoms: fatigue, musculoskeletal pain, difficulties with concentration or short-term memory, or all of these symptoms when experienced by patients despite resolution of the objective manifestations of infection by Borrelia burgdorferi after antibiotic treatment. Seen in a minority of patients.

post-Lyme disease syndrome: symptoms above lasting longer than six months

chronic Lyme disease: The term has been applied to patients in a variety of contexts, including those with objective late manifestations (such as arthritis) and those with purely subjective complaints after antibiotic therapy. It is also applied to those with unexplained subjective symptoms without credible laboratory evidence for Borrelia burgdorferi infection irrespective of exposure to an endemic area. The term has also been applied to patients with other identifiable conditions such as multiple sclerosis.

Source: G. Wormser


Also see IDSA resources on Lyme disease at www.idsociety.org/lymedisease.htm.  

Slides from this session and many others from IDSA 2007 are available online.

Audio files, including a full-conference CD-ROM, are available for purchase from Sound Images.


< Previous Article | Next Article >

Thinking Outside the Box
ART, Circumcision, STI Treatment as HIV Prevention
Global Surveillance, Vaccine Use Key to Controlling Seasonal Influenza
Bad Bugs on the Run
IDSA Advocacy Update
HIV PrEP: Should We or Shouldn’t We?
Keep Up with Drug Approvals, Recalls, Adverse Events
Lyme Disease: When Symptoms Don’t Improve
Alternative Approaches, Possible Vaccines Against MRSA Infections
New Hope for Viral Suppression in All HIV Patients
Resistant Staph: Use One Drug or a Combination?
Congratulations to the 2007 Society Award Recipients
Winners of the 2007 IDSA/SHEA Advancements in MRSA Awards
Congratulations to This Year’s 50 Outstanding Scholars!
IDSA Announces New Board Members
Welcome, New IDSA Members!
Electronic Tools for Infectious Diseases Practitioners
From the President
Public Reporting of HAIs May Have Unintended Consequences
Treatment Options for C. difficile
XDR TB: Where it Came From, Where We’re Going
Search Back Issues
Forward this Issue
Print-Friendly Version

© Copyright IDSA 2008 Infectious Diseases Society of America 1300 Wilson Boulevard, Suite 300 Arlington, VA 22209 info@idsociety.org

Home Page Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA